Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Autor: Carlo Salvarani, Dominique Baeten, Lai-Shan Tam, David B. Hall, Alan M. Solinger, Steven J. Padula, Tae-Hwan Kim, Chandrasena Pamulapati, Paul Scholl, James Cheng-Chung Wei, Mikkel Østergaard, Joachim Sieper, Pentti Järvinen, Stella Aslanyan, Sudha Visvanathan, Yakov Datsenko

Publikováno v: Annals of the Rheumatic Diseases
Baeten, D, Østergaard, M, Wei, J C-C, Sieper, J, Järvinen, P, Tam, L-S, Salvarani, C, Kim, T-H, Solinger, A, Datsenko, Y, Pamulapati, C, Visvanathan, S, Hall, D B, Aslanyan, S, Scholl, P & Padula, S J 2018, ' Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis : results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study ', Annals of the Rheumatic Diseases, vol. 77, no. 9, pp. 1295-1302 . https://doi.org/10.1136/annrheumdis-2018-213328
Annals of the rheumatic diseases, 77(9), 1295-1302. BMJ Publishing Group

ObjectivesTo evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).MethodsA total of 159 patients with biological-na�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff74393412a5f8c7bb73f2246c6abbaa
https://hdl.handle.net/11380/1167263

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

Autor: Ahmet Gül, Bahar Artım Esen, Charles A. Dinarello, Alan M. Solinger, Leonid L. Reznikov, A. M. Mirza, Patrick J. Scannon, Ilknur Tugal-Tutkun

Publikováno v: Annals of the Rheumatic Diseases. 71:563-566

Objective Uveitis and retinal vasculitis are sight-threatening manifestations of Behcet9s disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8aa9a4f962a3ad8ecd2098a8b1376f5
https://doi.org/10.1136/annrheumdis-2011-155143

Rheumatic manifestations of human immunodeficiency virus

Autor: Alan M. Solinger

Publikováno v: Current Rheumatology Reports. 5:205-209

Since July 1983, various rheumatic, musculoskeletal, or other immune disorders characterized by dysregulation have been associated with HIV and AIDS. Infections occur, but with a lower frequency than expected in a patient population with a disorder p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b312859dcb4c5b2f39011a435b72867e
https://doi.org/10.1007/s11926-003-0068-7

Right Axillary Thoracotomy Should Be the Standard of Care for Repair of Non-Complex Congenital Heart Defects in Infants and Children.

Autor: Said, Sameh M.^1,2 (AUTHOR) Sameh.Said@wmchealth.org, Essa, Yasin¹ (AUTHOR)

Publikováno v: Congenital Heart Disease. 2024, Vol. 19 Issue 4, p407-417. 11p.

Induction of Autoantibodies by Human Immunodeficiency Virus Infection and Their Significance

Autor: Evelyn V. Hess, Alan M. Solinger

Publikováno v: Rheumatic Disease Clinics of North America. 17:157-176

SUMMARY Although many of the changes in HIV and AIDS appear to be global, on closer investigation the defects are specific and can be explained by recognized mechanisms. Despite a demonstrated concurrent polyclonal B-cell activation, studies fail to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::638612e30094ef187c1eb24c289d773a
https://doi.org/10.1016/s0889-857x(21)00095-8